2-chloro-2-(2-chlorophenyl)acetonitrile | 5829-89-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-2-(2-chlorophenyl)acetonitrile
• 英文别名: (+/-)-α-chloro-(2-chlorophenyl)-acetonitrile；(+/-)α-chloro-2-(2-chlorophenyl)acetonitrile
• CAS: 5829-89-0
• 化学式: C₈H₅Cl₂N
• 分子量: 186.04
• InChiKey: MLWYHTPUZYQZSY-UHFFFAOYSA-N

物化性质

• 沸点：
  263.3±25.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-2-(2-chlorophenyl)acetonitrile 生成 2-Brom-4-acetamino-5-(2-chlorphenyl)thiazol
  参考文献：
  名称：

  Polyfunctional Aliphatic Compounds. IV. The Cyclization of Nitriles by Halogen Acids. A New Synthesis of Thiazoles

  摘要：

  DOI：

  10.1021/jo01042a036
• 作为产物：
  描述：

  邻氯苯乙腈 在 氯 作用下， 反应 6.0h， 以85.5%的产率得到2-chloro-2-(2-chlorophenyl)acetonitrile
  参考文献：
  名称：

  EP1942110

  摘要：

  公开号：

文献信息

• Azole-phenyl urea derivatives as ACAT inhibitors and their production
  申请人：NIHON NOHYAKU CO., LTD.

  公开号：EP0761658A1

  公开（公告）日：1997-03-12

  The present invention relates to azole-phenyl urea derivatives represented by the general formula (I): [wherein each of R1, R2 and R3 is H, halogen, C1-8alkyl or the like, and A is a group represented by the formula (i) or (ii): (wherein R4, R5, R6 and X are as defined in the specification.)] and a pharmacologically acceptable salt thereof, which have ACAT-inhibitory activity and are useful as a prophylactic and therapeutic agent for hypercholesterolemia, atherosclerosis and various diseases caused by them; a process for producing said derivative; and an ACAT inhibitor containing said derivative or salt as an active ingredient.

  本发明涉及一种由通式（I）表示的唑-苯基脲衍生物： [其中R1、R2和R3中的每一个是H、卤素、C1-8烷基或类似物，A是由式（i）或（ii）表示的基团： （其中R4、R5、R6和X如规范中定义。）]及其药理学上可接受的盐，具有ACAT抑制活性，并可用作高胆固醇血症、动脉粥样硬化及由其引起的各种疾病的预防和治疗剂；生产该衍生物的方法；以及含有该衍生物或盐作为活性成分的ACAT抑制剂。
• Preparation of Clopidogrel and Its Analogues Methyl Tetrahydrothienopyridine Acetate Compuunds
  申请人：Wang Lixin

  公开号：US20080249311A1

  公开（公告）日：2008-10-09

  The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.

  本发明揭示了一种使用卤代苯基乙腈（VIII）作为起始材料和四氢噻吡啶乙腈（IV）、四氢噻吡啶醋酸酯（V）作为关键中间体，进一步利用动力学分辨制备光学活性的氯吡格雷和化合物的制备方法。本发明的氯吡格雷是一种新型高效且安全的抑制血小板聚集的药物。该发明应用了系统技术对不需要的光学活性对映异构体进行消旋，回收和再利用分辨剂等，具有更大的经济优势，适用于商业规模的工业生产。其中：X代表氢、氟、氯、溴或碘原子，M代表碱金属离子。
• Compounds and compositions as protein kinase inhibitors
  申请人：Ding Qiang

  公开号：US20050187230A1

  公开（公告）日：2005-08-25

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.

  本发明提供了一类新型化合物，包括这些化合物的药物组合物，并使用这些化合物治疗或预防与异常或非调节激酶活性相关的疾病或紊乱，特别是涉及 Abl、BCR-Abl、CSK、JNK1、JNK2、PDGF-R、p38、p70S6K、TGFβ、SRC、EGFR、c-Kit、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6 和 SAPK2β 激酶异常激活的疾病或紊乱的方法。
• Process for the alpha-chlorination of phenylacetonitriles
  申请人：DSM N.V.

  公开号：EP0518412A1

  公开（公告）日：1992-12-16

  Process for the α-chlorination of phenylacetonitriles, for example benzyl cyanide, in which the phenylacetonitrile is contacted with a suitable chlorinating agent, sulphuryl chloride or chlorine gas, while an amount of strong acid, preferably HCl, is also present in the reaction mixture. The induction time and the reaction rate are dependent on, among other factors, the concentration of the acid. Preferably, the reaction is carried out under pressure. The reaction is well controllable.

  苯乙腈（例如苄基氰）的α-氯化工艺，其中苯乙腈与合适的氯化剂、硫酰氯或氯气接触，同时反应混合物中还含有一定量的强酸，最好是盐酸。诱导时间和反应速率取决于酸的浓度等因素。反应最好在压力下进行。该反应具有良好的可控性。
• PREPARATION OF CLOPIDOGREL AND ITS ANALOGUES METHYL TETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS
  申请人：Zhejiang Huahai Pharmaceutical Co., Ltd.

  公开号：EP1942110A1

  公开（公告）日：2008-07-09

  The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.

  本发明公开了一种以卤代苯乙腈(VIII)为起始原料，以四氢噻吩吡啶乙腈(IV)、四氢噻吩吡啶乙酸酯（V）为关键中间体，进一步利用动力学解析法制备出光学活性氯吡格雷和式(XII)的四氢塞那吡啶乙酸甲酯化合物。本发明的氯吡格雷是一种新型高效安全的抑制血小板聚集的药物。本发明采用系统的技术，对不需要的光学活性对映体进行消旋化，回收循环再利用解析剂等，具有较大的经济优势，适合商业化规模的工业生产。 其中X 代表氢原子、氟原子、氯原子、溴原子或碘原子，M 代表碱金属离子。